Expert Review of Anticancer Therapy

Papers
(The TQCC of Expert Review of Anticancer Therapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Triple-negative breast cancer: promising prognostic biomarkers currently in development82
TIM-3 pathway dysregulation and targeting in cancer55
Molecular therapeutic targets in non-small cell lung cancer49
CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis40
TKIs in combination with immunotherapy for hepatocellular carcinoma38
Research progress in strategies to improve the efficacy and safety of doxorubicin for cancer chemotherapy34
The potential of PSMA-targeted alpha therapy in the management of prostate cancer30
Clinical risk factors for mortality in patients with cancer and COVID-19: a systematic review and meta-analysis of recent observational studies28
The effects of exercise on cancer-related fatigue in breast cancer patients during primary treatment: a meta-analysis and systematic review28
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer27
Current radiotherapy techniques in NSCLC: challenges and potential solutions24
Optimal treatment in locally advanced cervical cancer23
The emerging role of antibody-drug conjugates in urothelial carcinoma23
Treatment of recurrent glioblastoma: state-of-the-art and future perspectives23
Pediatric relapsed acute myeloid leukemia: a systematic review23
The role of the microbiome in drug resistance in gastrointestinal cancers21
How can we turn the PI3K/AKT/mTOR pathway down? Insights into inhibition and treatment of cancer21
What is the best clinical approach to recurrent/refractory osteosarcoma?20
Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies20
New insights into ErbB3 function and therapeutic targeting in cancer20
Atezolizumab and pembrolizumab in triple-negative breast cancer: a meta-analysis19
Predicting pathological response to chemoradiotherapy for rectal cancer: a systematic review18
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy18
Palliative care for advanced gastric cancer18
Gender discrepancies in bladder cancer: potential explanations17
Pluripotency inducing Yamanaka factors: role in stemness and chemoresistance of liver cancer17
Radiomics features as predictive and prognostic biomarkers in NSCLC17
Is smoking an independent risk factor for developing cervical intra-epithelial neoplasia and cervical cancer? A systematic review and meta-analysis17
Pembrolizumab for advanced cervical cancer: safety and efficacy17
PARP inhibition in treatment of pancreatic cancer16
Surgical management of intrahepatic cholangiocarcinoma16
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy16
A multimodal approach to cancer-related cachexia: from theory to practice16
COVID-19: how will this impact children with cancer, now and in the future?15
Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma14
MRI radiomics in the prediction of therapeutic response to neoadjuvant therapy for locoregionally advanced rectal cancer: a systematic review14
Apoferritin: a potential nanocarrier for cancer imaging and drug delivery14
Should triple-positive breast cancer be recognized as a distinct subtype?14
The RACE for children act at one year: progress in pediatric development of molecularly targeted oncology drugs14
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors14
Amivantamab for the treatment ofEGFRexon 20 insertion mutant non-small cell lung cancer14
Immunosenescence, inflammaging, and cancer immunotherapy efficacy13
microRNAs as biomarkers of ovarian cancer13
Novel therapeutic drug strategies to tackle immune-oncological challenges faced by cancer patients during COVID-1913
Osteolytic metastasis in breast cancer: effective prevention strategies13
Cholangiocarcinoma: investigations into pathway-targeted therapies13
Applying immune-related lncRNA pairs to construct a prognostic signature and predict the immune landscape of stomach adenocarcinoma12
The emerging role of PARP inhibitors in prostate cancer12
Pembrolizumab in the first-line treatment of advanced head and neck cancer12
Promising predictors of checkpoint inhibitor response in NSCLC12
Piflufolastat F-18 (18F-DCFPyL) for PSMA PET imaging in prostate cancer 12
The diagnostic challenges of patients with carcinoma of unknown primary12
Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma11
Prognostic and clinicopathological value of BUB1B expression in patients with lung adenocarcinoma: a meta-analysis11
Radiation therapy and immunotherapy in breast cancer treatment: preliminary data and perspectives11
Clinical management of squamous cell carcinoma of the tongue: patients not eligible for free flaps, a systematic review of the literature11
Advances in systemic therapy for the first-line treatment of unresectable HCC11
Neoadjuvant therapy for muscle-invasive bladder cancer11
Prostate re-irradiation: current concerns and future perspectives11
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors11
Combined endocrine and targeted therapy in luminal breast cancer11
Further understanding of glioma mechanisms of pathogenesis: implications for therapeutic development11
Radiotherapy in the era of COVID-1911
Metronomic therapy in advanced breast cancer and NSCLC: vinorelbine as a paradigm of recent progress11
Management of oligometastatic and oligoprogressive renal cell carcinoma: state of the art and future directions11
The potential of cystatin C as a predictive biomarker in breast cancer10
The mechanisms of resistance to second- and third-generation ALK inhibitors and strategies to overcome such resistance10
Cemiplimab for locally advanced and metastatic basal cell carcinoma10
Measurable residual disease in pediatric acute myeloid leukemia: a systematic review10
Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm10
Antitumor effects of the multi-target tyrosine kinase inhibitor cabozantinib: a comprehensive review of the preclinical evidence10
Ribociclib plus fulvestrant in the treatment of breast cancer9
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype9
A multidisciplinary approach to soft-tissue sarcoma of the extremities9
Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors9
Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma9
Outcome of pediatric acute myeloid leukemia (AML) in low- and middle-income countries: a systematic review of the literature9
Brain metastases in metastatic cancer: a review of recent advances in systemic therapies9
The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma9
The impact of nutritional status on pancreatic cancer therapy9
Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method9
Current clinical management of elderly patients with glioma9
Targeted treatment options for the management of metastatic/persistent and recurrent cervical cancer9
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem9
Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy9
The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies9
Real-world evidence of the efficacy and tolerability of trabectedin in patients with advanced soft-tissue sarcoma8
Immune checkpoint inhibitors for recurrent endometrial cancer8
Pemigatinib in cholangiocarcinoma with a FGFR2 rearrangement or fusion8
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma8
Factors associated with early lung cancer mortality: a systematic review8
Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer8
Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer8
Checkpoint inhibitors in NSCLC for the elderly: current challenges and perspectives8
Overview of the synergistic use of radiotherapy and immunotherapy in cancer treatment: current challenges and scopes of improvement8
Treatment of cervical cancer: overcoming challenges in access to brachytherapy8
Immune checkpoint inhibition in classical hodgkin lymphoma8
Therapeutic options in thymomas and thymic carcinomas8
Detection ofMETexon 14 skipping mutations in non-small cell lung cancer: overview and community perspective8
Evaluating new treatments for anaplastic thyroid cancer8
Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy8
Development of chemotherapeutics for unresectable advanced esophageal cancer8
Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma7
Immunotherapy in soft tissue sarcoma: current evidence and future perspectives in a variegated family of different tumor7
miRNA and mRNA expression profiling reveals potential biomarkers for metastatic cutaneous melanoma7
Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis7
The need for new algorithms of treatment sequencing in clear-cell metastatic renal cell carcinoma7
Current developments in the combination therapy of relapsed/refractory multiple myeloma7
What are the advantages of neoadjuvant immunotherapy over adjuvant immunotherapy?7
Efficacy and safety of afatinib for non-small-cell lung cancer: state-of-the-art and future perspectives7
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis7
High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL)7
Endoscopic surveillance of colorectal cancer in inflammatory bowel diseases: a review of the literature7
Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma7
Tackling metastatic triple-negative breast cancer with sacituzumab govitecan7
Targeting the PI3K pathway in myeloproliferative neoplasms7
Prostate-specific membrane antigen targeted PET/CT for recurrent prostate cancer: a clinician’s guide7
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review6
Measurable residual disease of acute lymphoblastic leukemia in allograft settings: how to evaluate and intervene6
Surgical oncology in the age of multimodality therapy for cancer of the upper and lower gastrointestinal tract6
Lutetium Lu 177 vipivotide tetraxetan for metastatic castration-resistant prostate cancer6
Review of the recent clinical trials for PD-1/PD-L1 based lung cancer immunotherapy6
Distinguishing multiple lung primaries from intra-pulmonary metastases and treatment implications6
The MAP kinase signal transduction pathway: promising therapeutic targets used in the treatment of melanoma6
Treatment of BRAF-V600E mutant metastatic colorectal cancer: new insights and biomarkers6
Ribociclib efficacy in special populations and analysis of patient-reported outcomes in the MONALEESA trials6
Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer6
Curative therapy for rectal cancer6
Developments in personalized therapy for metastatic renal cell carcinoma6
Immunotherapy as a partner for HER2-directed therapies6
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer6
Pathology and systemic therapy of non-clear cell renal cell carcinoma: an overview6
Risk factors for the development of local recurrence in extremity soft-tissue sarcoma6
LAG-3 is a promising inhibitory immune checkpoint for antitumor immunotherapy6
Glasdegib in newly diagnosed acute myeloid leukemia6
Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer6
Surveillance for hepatocellular carcinoma: current status and future perspectives for improvement6
A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma6
Neratinib plus capecitabine for the treatment of advanced HER2-positive breast cancer6
Efficacy and safety of multi-kinase inhibitors in patients with radioiodine-refractory differentiated thyroid cancer: a systematic review and meta-analysis of clinical trials6
Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity6
0.029665946960449